Dong Fang Liu
Chief Tech/Sci/R&D Officer at NUVATION BIO INC.
Net worth: 15 720 $ as of 2024-04-29
Dong Fang Liu active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NUVATION BIO INC. | Chief Tech/Sci/R&D Officer | 2022-07-17 | - |
Career history of Dong Fang Liu
Former positions of Dong Fang Liu
| Companies | Position | Start | End |
|---|---|---|---|
| 3D MEDICINES INC. | Chief Tech/Sci/R&D Officer | 2019-01-10 | 2021-02-28 |
| CELGENE | Director/Board Member | - | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Training of Dong Fang Liu
| Beijing Medical University | Undergraduate Degree |
| University of Toledo (Ohio) | Graduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistics
International
| United States | 6 |
| China | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| 3D MEDICINES INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NUVATION BIO INC. | Health Technology |
| Private companies | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Stock Market
- Insiders
- Dong Fang Liu
- Experience
